Regional Analysis
Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Regional Insights
- North America is expected to be the largest market for Allan-Herndon-Dudley Syndrome (AHDS) during the forecast period, accounting for over 35.7% of the market share in 2023. North America has established itself as the dominant regional market for Allan-Herndon-Dudley syndrome (AHDS). This is due to a strong healthcare infrastructure and expenditure in countries like the U.S. along with the widespread presence of major manufacturers operating production facilities in the region.
- Asia Pacific is expected to be the second-largest market for Allan-Herndon-Dudley syndrome (AHDS), accounting for over 25.2% of the market share in 2023. The Asia Pacific region has emerged as the fastest expanding Allan-Herndon-Dudley syndrome (AHDS) market globally. Countries like China, India, Japan, and South Korea have growing healthcare needs of their large and rapidly developing populations.
- Europe is expected to be the fastest-growing market for Allan-Herndon-Dudley syndrome (AHDS), with a share of 19% during the forecast period. The growth of the market in Europe is due to the increasing prevalence of the disease in the region.
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
U.S.: 
U.K. : 
India : 
